donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
02633 Jacobson Pharma Corporation
0.700
+0.030+4.48%
YOY
Do not show
Hide blank lines
(FY)2022/03/31(Q6)2021/09/30(FY)2021/03/31(Q6)2020/09/30
Per Share IndicaTor
Operating Cash Flow Per Share
-- -- 35.08% 0.161 17.19% 0.2116 -6.57% 0.1192
Cash Flow Per Share
-- -- -2.58% 0.0297 128.34% 0.0296 -29.93% 0.0304
Operating Income Per Share
10.35% 0.8249 7.91% 0.388 -4.79% 0.7475 -16.86% 0.3595
Net Asset Per Share
4.25% 1.288 -7.9% 1.2583 -2.56% 1.2356 3.25% 1.3662
Basic Earning Per Share
2.21% 0.0927 -21.87% 0.0418 -16.56% 0.0907 -15.35% 0.0535
Diluted  Earning Per Share
2.21% 0.0927 -21.87% 0.0418 -16.56% 0.0907 -15.35% 0.0535
Profitability
Gross Profit Ratio
0.22% 38.891% -5.04% 36.359% -11.62% 38.805% -6.91% 38.287%
Operating Profit Ratio
-7.73% 16.351% -26.23% 15.574% -12.48% 17.722% -1.95% 21.113%
Net Profit Ratio
-8.7% 11.764% -31.72% 11.042% -7.59% 12.885% 6.88% 16.170%
Earning Before Tax Ratio
-4.91% 14.505% -26.11% 13.580% -9.02% 15.255% 0.08% 18.379%
ROE
3.25% 7.280% -16.15% 3.319% -15.23% 7.051% -17.34% 3.958%
ROA
0.41% 3.693% -24.45% 1.649% -24.61% 3.677% -23.48% 2.183%
Yield Quality
Operating Profit To Total Profits
-2.97% 112.727% -0.17% 114.685% -3.81% 116.172% -2.02% 114.875%
Tax To Total Profits
-21.63% -18.894% -55.5% -18.691% 11.07% -15.534% 31.77% -12.020%
Operating Cash To Total Revenue
-- -- 25.18% 41.511% 23.09% 28.304% 12.38% 33.161%
Capital Structure
Debt Assets Ratio
-8.33% 37.800% -5.56% 39.925% -4.33% 41.236% 2.45% 42.276%
Equity Multipler
-6.27% 1.9088 9.19% 1.9879 12.84% 2.0366 4.25% 1.8206
Debt Equity Ratio
-13.4% 60.771% -9.26% 66.458% -7.36% 70.174% 4.24% 73.239%
Current Assets To tatal Assets
3.89% 24.776% 4.84% 25.241% -6.67% 23.849% -18.57% 24.076%
Non Current Assets To Total Assets
-1.22% 75.224% -1.54% 74.759% 2.29% 76.151% 7.8% 75.924%
Current Liabilities To tatal Liabilities
5.58% 45.972% -22.03% 50.473% 18.18% 43.542% 27.63% 64.735%
Non Current Liabilities To Total Liabilities
-4.3% 54.028% 40.44% 49.527% -10.6% 56.458% -28.44% 35.265%
Solvency
Current Ratio
7.34% 1.4258 42.39% 1.2526 -17.45% 1.3283 -37.73% 0.8797
Quick Ratio
13.52% 1.0451 57.63% 0.9248 -16.18% 0.9207 -42.89% 0.5867
Operating Profit To Current Liabilities
7.67% 0.3157 7.49% 0.1199 -32.98% 0.2932 -42.08% 0.1115
Operrating Cash Flow To Current Liabilities
-- -- 82.42% 0.3195 -5.74% 0.4683 -33.62% 0.1752
Share Equity Without Minority Interest To Total Liabilities
16.39% 1.3859 -3.02% 1.26 -7.37% 1.1907 -6.37% 1.2993
Operating Cash Flow To Total Liabilities
-- -- 42.23% 0.1613 11.39% 0.2039 -15.28% 0.1134
Operating Profit To Total Liabilities
13.68% 0.1451 -16.19% 0.0605 -20.8% 0.1277 -26.08% 0.0722
Operating Capacity
Current Assets Turnover(T)
9.98% 1.3643 5.49% 0.6301 -4.7% 1.2405 -10.2% 0.5973
Fixed Assets Turnover(T)
-2.96% 1.0448 -18.95% 0.4856 -24.85% 1.0766 -24.19% 0.5991
Total Assets Turnover(T)
8.34% 0.3316 4.41% 0.1546 -13.9% 0.3061 -24.24% 0.1481
Growth Ability
Operating Revenue GR 3Y
3.55% -6.400% -25.91% -8.067% -126.42% -6.636% -112.45% -6.407%
Gross Income GR 3Y
8.89% -5.473% 4.47% -6.534% -123.59% -6.007% -112.95% -6.840%
Operating Profit GR 3Y
-122.76% -30.719% -186.97% -26.331% -139.1% -13.790% -78.32% 30.275%
EBT GR 3Y
-117.59% -26.550% -167.83% -19.892% -163.91% -12.202% -73.21% 29.326%
Net Profit GR 3Y
-202.38% -27.437% -156.11% -19.847% -143.46% -9.074% -71.11% 35.375%
Net Profit Attributable To The Parent Company GR 3Y
-106.06% -29.093% -164.94% -17.935% -169.74% -14.118% -77.55% 27.616%
Total Assets GR 3Y
-66.6% 11.617% -69.17% 17.534% -35.84% 34.781% -35.24% 56.865%
Share Equity Without Minority Interest GR 3Y
-128.09% -5.887% -107.63% -3.514% -53.49% 20.958% -32.72% 46.047%
Equity GR 3Y
-76.25% 10.079% -73.38% 13.512% -9.79% 42.437% -24.66% 50.757%
Total Liabilities GR 3Y
-43.46% 14.244% -63.44% 24.151% -61.14% 25.191% -48.12% 66.051%
Basic Earning Per Share GR 3Y
-53.82% -28.582% -199.01% -20.833% -307.01% -18.582% -56.17% 21.041%
Net Assets Per Share GR 3Y
-114.23% -1.927% -98.53% 0.546% -57.14% 13.542% -19.78% 37.092%
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Jacobs Research Pharmaceutical Co., Ltd. is a Hong Kong company engaged in the manufacture and trading of generics and proprietary Chinese medicines. The company operates through two major divisions. The generic drugs Division develops, produces and distributes generic drugs for therapeutic purposes. At present, the branch business is mainly carried out in Hong Kong, China. Proprietary Chinese Medicine Division develops, manufactures and distributes traditional Chinese medicine. At present, the branch business is mainly carried out in Hong Kong, China.
CEO: Guangye Cen
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...